The key facts about the biomanufacturing sector

👉🏻 The Strasbourg School of Biotechnology launches ExA2Bio

The Strasbourg School of Biotechnology (ESBS) has officially launched the ExA2Bio project, a training program of excellence designed to support skills development in bioproduction and biotherapies. Funded as part of France 2030 and winner of the Skills and Jobs of the Future call for proposals, this project brings together academic and industrial players to address the shortage of technicians and engineers in the sector. Backed by the EASE (School of Science and Business) training facility, ExA2Bio offers an immersive approach in real aseptic conditions, focused on quality, process control, and automation. 

👉🏻 Montpellier, a new stronghold against autoimmune diseases

Sanofi and the Immun4Cure University Hospital Institute in Montpellier have announced the creation of a global center of excellence dedicated to therapeutic innovation against autoimmune and inflammatory diseases. This public-private partnership also involves the University Hospital, the university, and Inserm. Sanofi will contribute its expertise in bioproduction, toxicology, and regulation, as well as research and experimentation platforms, according to Les Echos. Meanwhile, the IHU has clinical data, patient cohorts, and collection infrastructure to better understand these diseases and optimize clinical trials. “This partnership allows us to combine academic, clinical, and industrial expertise,” says Prof. Christian Jorgensen, director of the IHU Immun4Cure.

👉🏻 AIS, a one-stop shop for streamlining innovation in healthcare

In an interview with Journal des Entreprises, Charles Edouard Escurat, CEO of the French Health Innovation Agency (AIS), reiterated its role as a “one-stop shop for start-ups, SMEs, and laboratories committed to the future of healthcare.” The AIS, which is particularly active in the field of bioproduction, has therefore made simplification one of its major priorities. “We are working to streamline procedures, particularly with regard to the circulation of biological samples and the speed of ‘Go/No Go’ regulatory opinions. The aim is to prevent young companies from becoming exhausted by administrative procedures.”